Correcting and replacing: applied dna to showcase linea ivt as a high-yield, dsrna-mitigated platform for the gmp manufacture of rna at the 4th annual mrna-based therapeutics summit

- this version removes the use of 'presentation' from the prior-issued headline - - linea™ ivt platform delivers all the benefits of conventional ivt without dsrna contamination - stony brook, ny / accesswire / july 29, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, will present a poster at the 4th annual mrna-based therapeutics summit taking place july 29 - 31, 2024, in boston. the poster presents the company's linea™ ivt platform - a combination of an enzymatically produced dna template (linea™ dna ivt template) coupled with a next-generation rna polymerase - as a solution to enable mrna producers to manufacture better mrna faster via simplified workflows and reduced double-stranded rna (dsrna) contamination.
APDN Ratings Summary
APDN Quant Ranking